Loading...
Loading...
Browse all stories on DeepNewz
VisitMain barriers to mosquito-based vaccines deployment by Dec 31, 2025?
Ethical Concerns • 25%
Logistical Issues • 25%
Informed Consent Challenges • 25%
Other • 25%
Reports from health organizations or research institutions
Gates-Funded Mosquitoes Deliver Malaria Vaccines with 89% Success, Raising Ethical Concerns
Jan 2, 2025, 03:43 PM
Researchers at the Leiden University Medical Center in the Netherlands, funded by the Bill & Melinda Gates Foundation with $1.57 million, have developed genetically modified mosquitoes capable of delivering malaria vaccines through their bites. This method, referred to as 'flying vaccinators,' was tested in clinical trials involving 43 participants and showed promising results, with 89% of those bitten by GA2-modified mosquitoes developing immunity. The genetically modified parasites used in the trials were designed to infect humans without causing illness, allowing the immune system to build resistance. While the approach has demonstrated potential in controlled settings, researchers acknowledge significant challenges in scaling it for widespread use, citing ethical concerns, logistical barriers, and the need for informed consent. The study, published in the New England Journal of Medicine, highlights the innovative use of mosquito behavior to combat malaria but raises debates over the implications of using such methods on a larger scale.
View original story
Efficacy below 50% • 25%
Efficacy between 50% and 75% • 25%
Efficacy between 75% and 90% • 25%
Efficacy above 90% • 25%
Mostly Negative • 25%
Mixed • 25%
Indifferent • 25%
Mostly Positive • 25%
Yes • 50%
No • 50%
Other • 25%
Funding shortages • 25%
Vaccine hesitancy • 25%
Logistical issues • 25%
Cost • 25%
Regulatory Approval • 25%
Adherence • 25%
Distribution • 25%
Successful with no adverse effects • 25%
Successful but with some adverse effects • 25%
Unsuccessful • 25%
Inconclusive • 25%
5 to 10 countries • 25%
No countries • 25%
1 to 4 countries • 25%
More than 10 countries • 25%
Distribution • 25%
Cost • 25%
Adherence • 25%
Regulatory approval • 25%
Antimalarial drugs • 25%
Indoor residual spraying • 25%
Insecticide-treated nets • 25%
Vaccine deployment • 25%
4-6 Countries • 25%
None • 25%
More than 6 Countries • 25%
1-3 Countries • 25%